Halloran Consulting Group has expanded its strategic capabilities with the addition of Mark Weinberg, M.D., MBA, who will serve as chief medical officer (CMO) and managing director. The addition of Weinberg to Halloran’s advisory services creates a unique offering to life sciences companies seeking CMO expertise as a key part of an on-demand, integrated development team.

Weinberg is a pharmaceutical physician and executive with more than 16 years of experience working in product development roles in small and large companies. As part of Halloran’s team of experienced life science advisors, he will provide senior-level medical counsel for regulatory and product development strategy as well as conduct due diligence related to product and company acquisition.

“Mark is a terrific fit for the Halloran team and our clients,” said Laurie Halloran, founder, president and CEO of Halloran Consulting. “Our client-focused approach now provides valuable on-demand CMO access as part of an integrated development team. Our key objectives are to provide clients with experts to define and execute product development strategy so they move expeditiously into and through clinical studies. We have a tremendous track record of helping clients drive their program and vendor management in a capital and time efficient manner, conserving resources and enabling an executive team to focus on running the company, not the development program. Mark’s insights will be vital for clients.”

“I had a fantastic experience working with Halloran on the client side, so when Laurie approached me about joining the company, the choice was clear,” said Dr. Weinberg. “As a client, I was an army of one, and Halloran became my team bringing VP to CRA-level expertise. I am excited to join a team known for strategic program leadership and clinical development expertise,” he noted, adding that a company’s decision of when to hire a CMO is a complex, yet highly important, one.

“By providing CMO access, Halloran has augmented its strategic development and operational talent offerings to a key sector in the life sciences and biotech arena,” he said. “I look forward to working with Laurie and her team in enabling these companies to effectively develop and execute their plans to reach the next inflection point efficiently and productively.”

Before joining Halloran, Weinberg worked at RestorGenex as senior vice president and head of development, and prior to joining RestorGenex, he was vice president of global clinical science at Astellas Pharma.